

53. (Currently Amended) ~~The A kit according to claim 52 further comprising an agonist peptide and a vector comprising a gene encoding CEA or a recombinantly produced CEA protein and~~ an immunostimulatory molecule.
54. (Previously presented) The kit according to claim 52, wherein said vector comprises a nucleic acid comprising the nucleic acid sequence encoding SEQ ID NO:2.
55. (Canceled)
56. 56. (Previously presented) The vector of claim 50, wherein the HLA Class I molecule is HLA-A2.
57. (Currently Amended) The nucleic acid molecule of claim 47, wherein said ~~nucleic acid encodes an~~ amino acid sequence which is capable of stimulating a CEA specific cytolytic cytotoxic T lymphocyte (CTL) response in a subject.
58. (Currently Amended) A composition comprising ~~a nucleic acid sequence encoding carcinoembryonic antigen (CEA) and a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5~~ the nucleic acid molecule of claim 47.
59. (Currently Amended) The composition of claim 58, ~~wherein said composition encodes an amino acid sequence~~ which is capable of stimulating a CEA specific cytolytic cytotoxic T lymphocyte (CTL) response in a subject.